

---

Signature

Date

## **MICHAEL M. TAKAMURA, M.D.**

California Neuropsychopharmacology  
Clinical Research Institute, LLC  
(CNRI - San Diego, LLC)  
446 26<sup>th</sup> Street, 6<sup>th</sup> Floor  
San Diego, CA 92102  
Office Phone: (619) 481-5252  
Administrative Fax (619)481-5288  
Administrative email: cnri@pacbell.net

### **Experience**

8/2010-present **COUNTY OF SAN DIEGO, Forensic Examination Unit** **San Diego, CA**

Half time forensic psychiatrist. Working closely with San Diego Superior Courts, doing a variety of criminal and civil forensics cases. Experience in competency to stand trial, sanity, Mentally Disordered Offender (MDO), LPS conservatorship, Pre-Sentencing, and Opiate Addiction Disposition evaluations. Experience with expert witness testimonies. Testified 50+ times for competency, 40+ times for MDOs, 100+ times for LPS. Familiarity with both bench and jury trials.  
References: David Naimark, MD, Matthew Carroll, MD.

12/2010-present **SAN DIEGO BEHAVIORAL HEALTH, LLC** **San Diego, CA**  
Staff Physician / Sub-investigator  
References: Tram Tran-Johnson, PharmD. PsyD., Christopher Benbow, MD

3/2010-present **AURORA BEHAVIORAL HEALTH CARE** **San Diego, CA**  
Part-Time Inpatient Psychiatrist and Clinical Service Director of Psychiatric Intensive Care Unit (PICU). Directed Adult Services Unit (open, voluntary) between 3/2010 to 9/2014. Responsibilities include clinical oversight of involuntary inpatient unit, directing treatment teams, supervising post-doc students, and meeting with utilization review staff to regularly coordinate care of patients, in addition to running monthly unit staff meetings to guide direction of clinical care issues. Since 2007, familiarity with treatment of active duty USMC, US Army, USN, USCG military, especially PTSD / TBI and substance abuse disorders. Familiarity of legal matters regarding involuntary hospitalization and long term care for severe & chronic mentally ill. References: Jim Plummer (CEO), Thomas Flanagan MD (Medical Director), Chris Benbow MD (chief of staff).

12/2007-present **CALIFORNIA NEUROPSYCHOPHARMACOLOGY** **San Diego, CA**  
**CLINICAL RESEARCH INSTITUTE (CNRI - San Diego)**  
Consult Physician / Sub-Investigator for a variety of clinical trials protocols in psychopharmacology.  
References: Tram Tran-Johnson, PharmD. PsyD., Christopher Benbow, MD

- 7/2006-present **PRIVATE PRACTICE, Adult and Forensic Psychiatrist** **Poway, CA**  
 Outpatient practice, part-time. Clinical and forensic diagnosis and treatment of psychiatric conditions. Specializations include primarily medication management of mood and anxiety disorders, substance abuse treatment (including Suboxone), and psychotic disorders, but also include short term/brief psychotherapy, EAP referrals, sex offender monitoring and treatment, worker's compensations cases (including treatment), and select criminal forensic cases. Familiarity with federal Longshore Act disability and Defense Based Act disability cases. State of California Certified Qualified Medical Examiner (QME) as of 11/2009 to present date, with expertise in state Subject Matter Expert panel for QMEs. QME/AME satellite offices located in: Chula Vista, Carlsbad, Clairemont, La Mesa (all in San Diego area). References: Bernard Bogard MD, Anna Carrillo MD, Joshua Hall, MD, Ph.D
- 3/2012-2/2014 **COUNTY OF SAN DIEGO, Conditional Release Program** **San Diego, CA**  
 Half time forensic psychiatrist, for CONREP. Overseeing 1026, 2972 patients who are released into the community. Work closely with a team of nurses, psychologists, and social workers in an ACT model program. Experience with testimony, report writing, group interview settings, and psychopharmacology of the Severely Mentally Ill (SMI) population. Reason for Leaving: Program closed down and given back to State of California. References: Douglas Smith, LCSW; Robyn Siota-Breeding, PsyD.
- 11/2008-2/2010 **KAISER PERMANENTE MEDICAL GROUP** **Point Loma, CA**  
 Per diem psychiatrist at CDRP (Chemical Dependency and Rehabilitation Program). Work in urgent care setting, Doing outpatient detoxes and admitting to inpatient unit, triage work, follow-up on outpatient basis. Psychoeducation, family intervention, staff support services performed. Suboxone certified. Left job to go back to inpatient directorship at Aurora Hospital. References: Lawrence Moodie MD (Medical Director), Vanessa Greenwood MD.
- 7/2006-5/2009 **AURORA BEHAVIORAL HEALTH CARE** **San Diego, CA**  
 Full-Time Inpatient Psychiatrist and Clinical Service Director of Outpatient Programs. Responsibilities include clinical oversight of Partial Hospitalization Program (PHP) and Intensive Outpatient Program (IOP), directing treatment teams, running group therapies, supervising post-doc students, and meeting with utilization review staff to regularly coordinate care of patients. References: Jim Plummer (CEO), Thomas Flanagan MD (Medical Director), Mitch Gluck (Admin Head).
- 12/2007-12/2008 **MEDICAL DIRECTOR (Psychiatry)** **El Cajon, CA**  
**CARESOUTH HOME HEALTH**  
 Medical Director of Psychiatry Division of Home Health Agency. Responsibilities include oversight and consultation of psychiatric home health nursing care, bimonthly treatment team meetings, public speaking engagements on behalf of CareSouth, and business development planning. Discontinued service due to program being phased out. References: Susan Erickson LVN, Sharon DePeralta RN/MBA, Suzette Kelley RN.

- 8/2005-9/2006 **PRIVATE PRACTICE, Psychiatrist** **Sherman Oaks, CA**  
 Outpatient psychiatry practice, part-time. Adult-Adolescent Mental Health Clinic. Experience in working with adults and select adolescents with a variety of psychiatric illness, including mood, anxiety, thought, and substance abuse disorders. Discontinued due to moving back to San Diego. References: Alex Korchmarev, M.D., Nelli Korchmarev, Business Mgr, and Margaret Altman, LCSW.
- 2/2005-9/2006 **PACIFIC HEALTH SYSTEMS** **La Mesa, CA**  
 Inpatient Psychiatrist for weekend coverage at 2 psychiatric hospitals: University Community Medical Center and Alvarado Parkway Institute. References: Dr. Saleem Ishaque, Mohammed Bari, Brad Sanders.
- 7/2004-9/2006 **PSYCHIATRIC CENTERS IN SAN DIEGO (PCSD)** **San Diego, CA**  
**Contract psychiatrist** for the San Diego Sheriff Department. Responsibilities include covering 4 local jails. Perform initial assessments, follow-up medication management visits, inpatient units, safety cells evaluations, and supportive therapy. References: Drs. Sabah Chammas (PCSD), Dee Ann Wong (PCSD), Ari Albala (PCSD), Earl Goldstein (SD Sheriffs).
- 8/2003-9/2006 **SHARP HEALTHCARE SYSTEMS** **San Diego, CA**  
**Inpatient Psychiatrist** for weekend coverage at 2 Sharp Hospitals: Sharp Mesa Vista and Sharp Grossmont. Includes Seclusion & Restraint Coverage. References: Drs. Michael Plopper (SMV), Brian Miller (GH), John Otis (GH).
- 6/2003-3/2005 **CAL PSYCH COVERAGE (CPC)** **La Mesa, CA**  
**Inpatient Unit Psychiatrist** for weekend coverage at 2 private psychiatric hospitals: Alvarado Parkway Institute and Aurora Behavioral Health. Work with Locked Intensive Care units, Forensic/INS units, Adolescent & Senior units, Open Adult Unit and Seclusion & Restraint Coverage. Discontinued when company closed 3/2005. References: Drs. Mike Lardon, David Marks, Bernard Bogard.
- 2/2003-1/2004 **REGISTRY OF PHYSICIAN SPECIALISTS** **Walnut Creek, CA**  
**Contract Outpatient Psychiatrist** at Pleasant Valley State Prison and Centinela State Prison of the California Dept of Corrections. Work with inmate population with emphasis on outpatient follow-up visits, emergency forensic evaluations, on-call responsibilities. Reason for leaving: other weekend work closer to San Diego.
- 2/2003-1/2004 **NATIONAL MEDICAL REGISTRY** **San Clemente, CA**  
**Contract Outpatient and Inpatient Psychiatrist** at Pleasant Valley State Prison and Centinela State Prison. Work with inmate population with emphasis on psychopharmacology, brief psychotherapy, especially with the sensitive-need (sexual predator, homosexual, ex-gang member) populations. References: Drs. Bill Alvarez (PVSP), Linda Francis (PVSP), Alan Abrams (CSP). Reason for leaving: other weekend work closer to San Diego.
- 6/1998-9/1998 **UCLA HEALTH SERVICES RESEARCH & DEPT. OF GERIATRICS** **Los Angeles, CA**  
**Principal Investigator** in a project to develop a disease-targeted quality-of-life (QOL) outcome assessment instrument for stroke patients. Co-investigators: Dr. Ron Hays, UCLA Health Services Research and RAND Corporation; Dr. Dilip Jeste, UCSD VA Geropsychiatry.

6/1996-12/1996 **HARVARD MEDICAL SCHOOL** **Cambridge, MA**  
**Research assistant** in the Laboratory of Neurophysiology. Collaborated in study concerning the cardiorespiratory mechanisms of REM sleep, a joint collaboration among Drs. James Allan Hobson, Richard Verrier, and James Quattrochi. Experience with neurosurgical techniques in cats, e.g. implanting EEG, EMG, EOG, as well as cholinergic and adrenergic pharmacology

## Education

7/2006-present **UNIVERSITY OF CALIFORNIA, SAN DIEGO** **La Jolla, CA**  
**Dept of Psychiatry**  
Assistant Clinical Voluntary Professor  
Responsibilities include weekly supervision of PGY-1 or 2 resident(s). Involves teaching of case discussions, journal article reviews, psychotherapy case formulations, medication treatment strategies, psychiatry and the law, and resident support and career mentoring.

6/2005-6/2006 **UNIVERSITY OF SOUTHERN CALIFORNIA** **Los Angeles, CA**  
**Dept of Psychiatry**  
Post-residency fellowship in forensic psychiatry.  
Fellow at the USC Institute of Psychiatry, Law and Behavioral Science  
USC Keck School of Medicine, Department of Psychiatry and Behavioral Science

### **Clinical:**

Psychiatric-Legal evaluations for attorneys and judges, in criminal, juvenile, and dependency law.

Treatment and Evaluation of Mentally Disordered Offenders.

### **Academic Appointments:**

Clinical Instructor in Psychiatry

7/1/05-7/1/06

USC Keck School of Medicine,

Dept of Psychiatry and Behavioral Science

### **Consultantships:**

Los Angeles County Superior Courts, including Department 95 Mental Health Court

Los Angeles County Public Defender's Office

Los Angeles County Alternate Public Defender's Office

Los Angeles County District Attorney's Office

Los Angeles County Sheriff's Department, Twin Towers Correctional Facility

Los Angeles City Police Department

Los Angeles County Department of Mental Health

Los Angeles County Department of Health

Los Angeles County Department of Probations

Los Angeles County Department of the Coroner

LAC+USC Medical Center

Patton State Hospital, Atascadero State Hospital, US Federal Courts

6/2001-6/2005 **UNIVERSITY OF CALIFORNIA, SAN DIEGO Dept of Psychiatry** **La Jolla, CA**  
Chief Resident Dept of Psychiatry, Veterans Administration Hospital 2004-2005  
UCSD Outpatient Center Dual Diagnosis Team Psychiatrist 2003-2004  
Resident physician in Dept of Psychiatry, PRITE scores 95<sup>th</sup>+ percentiles 2001-2005

**Awards:**

- *UCSD Housestaff Physician of the Year (one only; selected by all dept chairs) 2005-2006*
- *AADPRT Ginsburg Fellowship Award (seven in nation) 2005-2006*
- *APA/GlaxoSmithKline (Falk) Leadership Fellow Award (ten in nation) 2003-2005*
- *American College of Psychiatrists Laughlin Fellow Award (fifteen in nation) 2003-2004*
- *Medical Education & Research Foundation (MERF) Scholarship Recipient 2002-2004*
- *UCSD Kaiser Excellence-In-Teaching Award (two among UCSD housestaff) 2002-2003*

**Presentations:**

- APA 2005 Workshop on "A Bitter Bill: What Every Physician Needs to Know" May 2005
- APA 2004 Workshop on "Wherefore Neuroscience" Participant May 2004
- Dept of Psychiatry Grand Rounds Presenter: Time Limited Psychotherapy January 2004

**Other:**

License:

Medical Board Of California, November 22, 2002, DEA November 30, 2002

Research: Senior research project studying effects of chemotherapy and depression on sleep variables in breast cancer patients, with Dr. Sonia Ancoli-Israel.

9/1997-6/2001 **UNIVERSITY OF CALIFORNIA, SAN DIEGO School of Medicine La Jolla, CA**  
Earned M.D. degree from the School of Medicine  
Honors: Psychiatry clerkship, inpatient medicine, outpatient psychiatry, emergency psychiatry, outpatient medicine, emergency toxicology, and inpatient cardiology. OSCE exam: 2<sup>nd</sup> highest grade in class.  
4<sup>th</sup> highest grade in class on CPX patient exam. Near honors: neurology, pediatrics.

**Honors/Awards:**

- UCSD School of Medicine 25th Anniversary Scholar (\$2000x4) (1997-2001)
- Japanese Medical Society of America: Pharmaceutical Group Scholarship Award (\$2000) (1998)
- Betty Ford Center Professional-In-Residence Program Scholarship (\$1500) (1998)
- American Federation for Aging Research (AFAR) Hartford UCLA Geriatrics Fellowship (\$4500) (1998)

**Other:**

- Professional memberships: AMA, APA, AAFP, American Society of Addiction Medicine, ACOEM

9/1993-6/1997 **HARVARD UNIVERSITY Cambridge, MA**  
Received Honors B.A. *cum laude* from the Dept. of Biology, with neuroscience focus.  
**GPA: 3.65**

**Honors:**

- Dean's List (1993-97)
- Harvard College Scholarship (1993-95)

- John Harvard Scholarship (1995-97)
- California State Robert Byrd Honors Scholarship (1993-97)
- Harvard Research Program Scholarship (1995)
- Winthrop House Best All-Around Award (1997)

## Personal

- Proficient in Japanese, Korean, and Spanish languages. Experience in interpreting and translating.
- Hobbies: piano, Japanese tea ceremony, classical music, bicycling, travel, fine dining.

## Other

- **AMERICAN PSYCHIATRIC ASSOCIATION:**

1. Member-In-Training (MIT) Representative 2002-2005, San Diego Psychiatric Society District Branch
2. Deputy Assembly Representative 6/2006-6/2008, San Diego Psychiatric Society District Branch.
3. Area 6 Early Career Psychiatrist Deputy Rep 6/2008-6/2010, California Psychiatric Association.
4. Area 6 Early Career Psychiatrist Rep 6/2010-6/2012, California Psychiatric Association
5. Assembly ECP Committee Chairperson, 5/2011-5/2012.
6. Assembly Executive Council (AEC) Member, 5/2011-5/2012.
7. Government Affairs Committee Member 2008-present, California Psychiatric Association.
8. California Psychiatric Association Access to Care Task Force member, 9/2011-5/2012.
9. APA Assembly - Reference Committee 4 Member, 2009-present.
10. Committee on Procedures Member (chaired by Glenn Martin, MD), 2010-2012.
11. Communications Champion Member (workgroup headed by Scott Benson, MD) 8/2011-5/2012.
12. Panelist – ECP Workshop “Transition to Practice and Transitions in Practice” May 2012 Mtg.
13. APA Nominations Subcommittee Member, 7/2011-5/2012.
14. San Diego Psychiatric Society – Council Member. County of San Diego Representative. 6/2013-present.

- **SAN DIEGO COUNTY MEDICAL SOCIETY:**

1. California Medical Association Young Physicians Rep, 2008-2012

### Other Professional Memberships:

- American Association of Psychiatry and the Law (AAPL),
  - California Psychiatric Association (CPA),
  - American-Korean Association of Psychiatrists, (AKAP),
  - California Society of Industrial Medicine and Surgery (CSIMS).
- **J. William Fulbright Scholarship** to Korea (1997-98)
  - Japan English Teaching (JET) program int'l relations coordinator fellowship (Japanese Ministry of Education), 1997
  - Panelist on economic development: 49th Annual Japan-America Student Conference (Kyoto, Japan 1997)
  - Translator for Members of Japanese House of Representatives, and Korean former Prime Minister, at the Asia-Pacific Forum (Harvard Kennedy School of Government)

## Good Clinical Practice Training:

- ICH Good Clinical Practice for Clinical Trial Sites - (Modules 1-6) provided by Quintiles Global Learning - Certificate of Completion - December 2016
- ICH GCP adapted for the US in English - GCP web-based training course designed and developed by INFONETICA Certificate No. 33214-46-36746, September 2014
- Good Clinical Practice for Investigational Site Staff 2.0 (identified by TransCelerate BioPharma, Inc) October 2013.
- Annual review of GCPs, Belmont Report, FDA Information Sheets

## Clinical Research Experience

### *Sub-Investigator for the following studies:*

1. Astra Zeneca Protocol 5077IL/0089: Multi-center, Open-label, Flexible-dose, Parallel-group, Evaluation of the Cataractogenic Potential of Seroquel and Risperdal in the Long Term Treatment of Patients with Schizophrenia or Schizoaffective Disorder. 2006 - 2008  
PI: Tran-Johnson
2. Pfizer Protocol A1281143: A 3-week, Double-blind, Multi-center, Placebo-controlled Study Evaluating the Efficacy and Safety of Add-on Oral Ziprasidone in Subjects with Acute Mania Treated with Lithium or Divalproex. 2006 - 2008 PI: Tran-Johnson
3. Sanofi-Aventis Protocol DRI6726: A 24-week, Multicenter, Double-blind, Randomized, Parallel-group, Dose-ranging Study of the Efficacy and Safety of Oral Doses of Study Drug and Placebo on Top of an Established Treatment Regimen of Either Olanzapine, Risperidone or Quetiapine Monotherapy in the Treatment of Cognitive Impairment in Schizophrenia. 2007 - 2009 PI: Tran-Johnson
4. Novartis Protocol CAGO178A2303: An 8-week, Multicenter, Randomized, Double-blind, Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Study Drug Given Once Daily in the Treatment of Major Depressive Disorder (MDD) Followed by a 52-week Open-label Treatment with Study Drug. 2007 - 2008 PI: Tran-Johnson
5. Ortho-McNeil-Janssen Protocol R076477-SCH-4013: A Blinded-initiation Study of Medication Satisfaction in Subjects with Schizophrenia Treated with Study Drug After Suboptimal Response to Oral Risperidone. 2007 - 2007 PI: Tran-Johnson
6. Dainippon Sumitomo Pharma Protocol D1050231: A Phase 3 Randomized, Placebo- and Active Comparator-controlled Clinical Trial to Study the Safety and Efficacy of Two Doses of Study Drug in Acutely Psychotic Patients with Schizophrenia. 2008 - 2008 PI: Tran-Johnson  
**FDA Audit in 2010 with no 483s.**
7. Protocol C10953/2032/DP/US: An 8-week, Double-blind, Placebo-controlled, Parallel-group, Fixed-dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/day) as Adjunctive therapy in Adults With Major Depression Associated With Bipolar I Disorder. 2008 - 2008 PI: Benbow
8. Alexza AMDC-004-301: A Multi-center, Randomized, Double-blind, Placebo-controlled, Multi-dose Efficacy and Safety Study of Staccato Loxapine for Inhalation in Schizophrenic Patients with Agitation. 2007 - 2008 PI: Tran-Johnson

9. Lundbeck Protocol 11723A: A Randomized, Double-blind, Parallel-group, Flexible-dose Study Exploring the Neurocognitive Effect of Study Drug Versus Quetiapine in Patients with Schizophrenia Using the MATRICS Concensus Cognitive Battery (MCCB). 2008 - 2008  
PI: Tran-Johnson
10. Sanofi-Aventis Protocol EFC10438: An Eight-week, Double-blind Study to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Dose of Study Drug Once Daily in Combination with Paroxetine 20mg Once Daily Compared to Placebo in Combination with Paroxetine 20mg Once Daily in Patients with Major Depressive Disorder. 2008 - 2009  
PI: Tran-Johnson
11. Corcept C-1073-14: A Double-blind, Placebo-controlled Study of the Efficacy and Safety of CORLUX (Mifepristone) Vs. Placebo in the Treatment of Psychotic Symptoms in Patients with Major Depressive Disorder with Psychotic Features. 2008 - 2014 PI: Tran-Johnson
12. Novartis CSPA100AUS01: An 8-week Multicenter, Randomized, Double-blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren Administered in Combination with Amlodipine (150/5 mg, 300/10 mg) versus Amlodipine alone (5 mg, 10 mg) in African American Patients with Stage 2 Hypertension. 2009 - 2009 PI: Tran-Johnson
13. Pfizer A1281139: A six-Week, Double-blind, Multicenter, Placebo-controlled Study Evaluating the Efficacy and Safety of Flexible Doses of Oral Ziprasidone in Outpatients with Bipolar I Depression. 2007 - 2008 PI: Tran-Johnson
14. Takeda LuAA21004\_303: A Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study Comparing the Efficacy and Safety of Lu AA21004 versus Placebo in Acute Treatment of Adults With Major Depressive Disorder. 2008 - 2008 PI: Tran-Johnson
15. Alexza Protocol AMDC-004-302: A Multi-centered, Randomized, Double-blind, Placebo-controlled, Multi-dose Efficacy and Safety Study of Staccato Loxapine for Inhalation in Patients with Bipolar I Disorder and Acute Agitation. 2008 - 2008 PI: Tran-Johnson
16. Alkermes ALK33-005: A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Adaptive Study of the Safety and Efficacy of RDC-0313 in Adults with Alcohol Dependence. 2010 - 2010 PI: Tran-Johnson
17. C10953/2034/SZ/MN: A 24-week, Double-blind, Placebo-controlled, Parallel-group, Fixed-dosage Study to Evaluate the Efficacy and Safety of Armodafinil (150, 200 and 250 mg/day) as Adjunctive Therapy in Adults With Schizophrenia. 2008 - 2010 PI: Tran-Johnson
18. Dainippon Sumitomo Pharma Protocol D1050235: A Randomized, 6-week, Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar I Depression. 2009 - 2011 PI: Tran-Johnson
19. Dainippon Sumitomo Pharma Protocol D1050236: A Randomized 6-week, Double-blind, Placebo-controlled, Fixed-flexible Dose, Parallel-group Study of Lurasidone for the Treatment of Bipolar I Depression. 2009 - 2010 PI: Tran-Johnson
20. Dainippon Sumitomo Pharma Protocol D1050237: Long-term Safety, Tolerability, and Effectiveness of Lurasidone in Subjects with Schizophrenia or Schizoaffective Disorder: A Randomized, Active Comparator-controlled Trial. 2009 - 2010 PI: Tran-Johnson
21. Dainippon Sumitomo Pharma Protocol D1050256: A 24-week, Flexible-dose, Open-label Extension Study of Lurasidone for the Treatment of Bipolar I Depression. 2009 - 2011  
PI: Tran-Johnson



22. Novartis Protocol CSPP100A2409: An 8-week, Randomized, Double-blind, Parallel-group, Multi-center, Active-controlled Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ (300/25 mg) Compared to Amlodipine (10 mg) in Patients with Stage 2 Systolic Hypertension and Diabetes Mellitus. 2009 - 2009 PI: Chen
23. Novartis Protocol CLCQ908A2203: A 12-week, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Adaptive Design Study to Evaluate the Efficacy on Blood Glucose Control and Safety of Five Doses of LCQ908 (2, 5, 10, 15 and 20 mg) or Sitagliptin 100mg on a Background Therapy of Metformin in Obese Patients with Type 2 Diabetes. 2009 - 2010 PI: Chen
24. Otsuka Protocol 31-07-247: A 38-week, Multicenter, Double-blind, Randomized, Active-controlled, Study to Evaluate the Long-term Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) in Patients with Schizophrenia. 2009 - 2011 PI: Tran-Johnson
25. Otsuka 331-07-203: A Phase 2, 6-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 Once Daily and Aripiprazole Once Daily for Treatment of Hospitalized Adult Patients with Acute Schizophrenia. 2009 - 2010 PI: Tran-Johnson
26. Otsuka Protocol 331-08-210: A Phase 2, Multicenter, Open-label Study to Assess the Safety and Tolerability of Oral OPC-34712 as Monotherapy in Adult Patients with Schizophrenia. 2009 - 2010 PI: Tran-Johnson
27. Pfizer A0081165: Effects of Pregabalin on Sleep Maintenance in Subjects with Fibromyalgia Syndrome and Sleep Maintenance Disturbance: A Randomized Placebo-controlled 2-way Crossover Polysomnography Study. 2009 - 2010 PI: Tran-Johnson
28. Otsuka 31-08-248: A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients with Schizophrenia. 2010 - 2011 PI: Tran-Johnson
29. Alkermes ALK33-005: A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Adaptive Study of the Safety and Efficacy of RDC-0313 in Adults with Alcohol Dependence. 2010 - 2010 PI: Tran-Johnson
30. Abbott M10-854: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS). 2010 - 2011 PI: Tran-Johnson
31. AstraZeneca Protocol D4130C00004: A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Phase III, Efficacy and Safety Study of 3 Fixed Dose Groups of TC-5214 (S-mecamylamine) as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy. 2010 - 2011 PI: Tran-Johnson
32. AstraZeneca Protocol D4130C00007: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III, Long-Term Safety and Tolerability Study of TC-5214 (S-mecamylamine) as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate response to Antidepressant Therapy. 2010 - 2012 PI: Tran-Johnson
33. Cephalon Protocol C10953/3072: A Double-blind, Placebo-controlled, Parallel-group, Fixed-dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 and 200 mg/day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder. 2010 - 2012 PI: Tran-Johnson

34. Cephalon Protocol C10953/3074: A 6-month, Open-label, Flexible-dosage (150 to 200 mg/day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults with Major Depression Associated With Bipolar I Disorder. 2011 - 2012 PI: Tran-Johnson
35. Ortho-McNeil-Janssen Protocol R092670-SCH-3006: A Fifteen-month, Prospective, Randomized, Active-controlled, Open-label, Flexible dose Study of Paliperidone Palmitate Compared with Oral Antipsychotic Treatment in Delaying Time to Treatment Failure in Adults with Schizophrenia Who Have Been Recently Released from Jail. 2010 - 2012 PI: Tran-Johnson
36. Novartis Protocol CAGO178C2301: An 8-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study of the Efficacy and Safety of Agomelatine 0.5 mg and 1 mg Sublingual Tablets Administered Once Daily in Patients with Major Depressive Disorder (MDD) 2010 - 2011 PI: Tran-Johnson
37. GlaxoSmithKline Protocol H3B113147: A Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Cognitive Enhancing Effect of GSK239512 in Stable Patients with Schizophrenia. 2011 - 2011 PI: Benbow
38. Novartis Protocol CILO522DUS01: A 12-week, Randomized, Multi-center, Open-label, iloperidone, (12-24mg/day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole (i-FANS). 2010 - 2011 PI: Tran-Johnson
39. Forest Protocol RGH-MD-36: An Inpatient Cariprazine Safety and Tolerability Study in Patients with Bipolar I Disorder, Current Episode Manic or Mixed. 2011 - 2011 PI: Tran-Johnson
40. Otsuka Protocol 31-08-255: A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an oral Aripiprazole/Escitalopram Combination Therapy in Patients with Major Depressive Disorder. 2010 - 2011 PI: Tran-Johnson
41. Otsuka Protocol 31-08-257: A Multicenter, 52-week, Open-label Study to Assess the Safety and Tolerability of an oral Aripiprazole/Escitalopram Combination Therapy in Patients with Major Depressive Disorder. 2011 - 2011 PI: Tran-Johnson
42. Ortho-McNeil-Janssen Protocol R092670-SCA-3004: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects with Schizoaffective Disorder. 2010 - 2013 PI: Tran-Johnson
43. Sunovion Protocol D1050289: A Randomized, 6-week, Open-label Study Evaluating the Safety, Tolerability, and Efficacy of Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched from other Antipsychotic Agents. 2012 - 2012 PI: Tran-Johnson
44. Sunovion Protocol D1050290: A 24-week, Flexible-dose, Open-label Extension Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder. 2012 - 2012 PI: Tran-Johnson
45. Novartis Protocol ILO522D2301: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients with Schizophrenia Receiving Either Flexible Dose Iloperidone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weeks of Open Label Extension. 2011 - 2014 PI: Tran-Johnson

46. Bristol-Myers Squibb Protocol CN162-006: A Multicenter, Randomized, Double-blind, Active-controlled Study of the Efficacy and Safety of Flexibly-Dosed BMS-820836 in Patients with Treatment Resistant Major Depression. 2011 - 2012 PI: Tran-Johnson
47. Bristol-Myers Squibb Protocol CN162-010: A Multicenter, Double-blind, 58-week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients with Treatment Resistant Major Depression. 2012 - 2013 PI: Tran-Johnson
48. Forest Protocol RGH-MD-05: A Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of Cariprazine in the Acute Exacerbation of Schizophrenia. 2011 - 2011 PI: Tran-Johnson
49. Forest Protocol RGH-MD-11: Evaluation of the Long-term Safety, Tolerability, and Pharmacokinetics of Cariprazine in Patients with Schizophrenia. 2010 - 2013 PI: Tran-Johnson
50. Forest Protocol RGH-MD-33: A Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder. 2011 - 2011 PI: Tran-Johnson
51. Lundbeck Protocol 13946A: A Randomized, Double-blind, Parallel-group, Explorative Study of the Safety, Tolerability and Pharmacokinetics of Daily Dosing Compared to Weekly Dosing of Zicronapine in Patients with Schizophrenia. 2011 - 2011 PI: Tran-Johnson
52. Otsuka Protocol 31-10-270: An Open-label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients with Schizophrenia. 2011 - 2013 PI: Tran-Johnson
53. Otsuka Protocol 31-11-289: An Open-label, Safety and Tolerability Trial of Aripiprazole IM Depot Treatment Initiation in Adult Subjects With Schizophrenia Stabilized on Atypical Oral Antipsychotics Other Than Aripiprazole. 2012 - 2012 PI: Tran-Johnson
54. Otsuka Protocol 331-10-230: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Fixed-dose OPC-34712 (4, 2, and 1 mg/day) in the Treatment of Adults with Acute Schizophrenia. 2011 - 2012 PI: Tran-Johnson
55. Otsuka Protocol 331-10-237: A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Maintenance Treatment in Adults with Schizophrenia. 2011 - 2015 PI: Tran-Johnson
56. Otsuka Protocol 331-10-242: A Parallel-arm, Double-blind, Placebo and Positive Controlled Multiple Oral Dose Administration Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects with Schizophrenia or Schizoaffective Disorder. 2011 - 2012 PI: Tran-Johnson
57. PharmaNeuroBoost Protocol PNB01-C301: Pipamperone/Citalopram(PNB01)versus Citalopram (CIT) and Versus Pipamperone (PIP) in Moderate to Severe Major Depressive Disorder (MDD): A Randomized, Double-blind Phase III Clinical Trial of 10 Weeks. 2011 - 2012 PI: Tran-Johnson
58. Roche Protocol NP25620: A Randomized, Double-blind, Parallel-group Study of the Safety and Efficacy of RO4917523 Versus Placebo, as Adjunctive Therapy in Patients with Major Depressive Disorder with Inadequate Response to Ongoing Antidepressant Treatment. 2011 - 2013 PI: Tran-Johnson
59. Sunovion Protocol D1050238: A Double-blind, Placebo-controlled Withdrawal Study of Lurasidone for the Maintenance Treatment of Subjects with Schizophrenia. 2011 - 2013 PI: Tran-Johnson

60. Targacept Protocol TC-5619-23-CRD-003 : A Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia (IND#102612). 2012 - 2013 PI: Tran-Johnson
61. Vanda Protocol VP-VEC-162-2301: A Multicenter, Randomized, Double-masked, Placebo-controlled, Parallel Study to Investigate the Safety and Efficacy of 20 MG Tasimelteon Versus Placebo in Adult Subjects with Major Depressive Disorder Followed by a 52-Week Open-label Extension. 2011 - 2013 PI: Tran-Johnson
62. Takeda Protocol Lu AA21004\_317: A Phase 3, Randomized Double-blind, Parallel-group, Placebo-controlled, Duloxetine-referenced, Fixed-dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 15 mg) of Lu AA21004 in Acute Treatment of Adults with Major Depressive Disorder. 2011 - 2012 PI: Benbow
63. Takeda Protocol Lu AA21004\_314: A Phase 3, Long-term, Open-label, Flexible-dose, Extension Study Evaluating the Safety and Tolerability of Lu AA21004 (15 and 20 mg) in Subjects with Major Depressive Disorder. 2011 - 2013 PI: Benbow
64. Sunovion Protocol D1050307: A 12-week, Multicenter, Open-label Extension Study in Subjects with Schizophrenia. 2012 - 2013 PI: Tran-Johnson
65. Schering-Plough Protocol P05692(formerly 041045): A Multicenter, Double-blind, Fixed-dose, Long-term Extension trial of the Safety of Asenapine in Subjects Diagnosed with Bipolar 1 Disorder Who Completed Protocol P05691 (formerly 041044). 2012 - 2014 PI: Tran-Johnson
66. Schering-Plough Protocol P05688(formerly 041038): A Multicenter, Randomized, Double-blind, Fixed-dose, 6-week Trial of the Efficacy and Safety of Asenapine Compared With Placebo Using Olanzapine as an Active Control in Subjects with an Acute Exacerbation of Schizophrenia. 2013 - 2013 PI: Tran-Johnson
67. Schering-Plough Protocol P05689(formerly 041039): A Multicenter, Double-blind, Fixed-dose, Long-term Extension Trial of the Safety of Asenapine using Olanzapine as an Active Control in Subjects Diagnosed with Schizophrenia who Completed Protocol P05688 (formerly 041038). 2013 - 2013 PI: Tran-Johnson
68. AbbVie Protocol M10-855: A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel-group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS) in Nonsmokers. 2013 - 2014 PI: Tran-Johnson
69. AbbVie Protocol M13-608: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS) in Smokers. 2013 - 2013 PI: Tran-Johnson
70. Novartis Protocol CAQW051A2207: A 12-Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients. 2012 - 2013 PI: Tran-Johnson
71. Otsuka Protocol 31-08-250: A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients with Bipolar Disorder. PI: Tran-Johnson

72. Otsuka Protocol 31-08-252: A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients with Bipolar I Disorder. 2014 - 2016 PI: Tran-Johnson
73. Otsuka Protocol 31-12-291: A 12-week, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults with Schizophrenia. 2012 - 2013 PI: Tran-Johnson
74. Otsuka Protocol 31-12-297: A 26-week, Multicenter, Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients with Schizophrenia. 2013 - 2014 PI: Tran-Johnson
75. Otsuka Protocol 331-10-231: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Three Fixed Doses of OPC-34712 in the Treatment of Adults with Acute Schizophrenia. 2013 - 2013 PI: Chen
76. Lundbeck Protocol 14724A : A 28-week, Randomised, Open-label Study Evaluating the Effectiveness of Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients with Schizophrenia. 2013 -2014 PI: Tran-Johnson
77. Sunovion Protocol D1050303: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Low-dose Lurasidone in Acutely Psychotic Subjects with Schizophrenia. 2013 - 2013 PI: Tran-Johnson
78. AbbVie Protocol M13-765: Long-term Safety and Efficacy of ABT-126 in Subjects with Schizophrenia: A Double-blind Extension Study for Subjects Completing Study M10-855. 2013 - 2014 PI: Tran-Johnson
79. Lundbeck Protocol 14724B : Interventional, Open-label, Flexible-dose Extension Study of Aripiprazole Once-monthly in Patients with Schizophrenia. 2013 - 2014 PI: Tran-Johnson
80. Otsuka Protocol 31-12-298: Safety and Tolerability of IM Depot Aripiprazole in subjects with schizophrenia. PI: Tran-Johnson
81. Forest Protocol RGH-MD-76: A Phase 3, Long-term, Open-label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder. 2013 - 2013 PI: Tran-Johnson
82. Roche Protocol BP28865 : Multi-center Cognition Assessment in Healthy Subjects to Collect Reference Data for Comparison to Patients with Depression. 2013 - 2014 PI: Tran-Johnson
83. Pfizer Protocol A8241019 : A 12-week, Randomized, Phase 2, Double-blind, Parallel-group Study of Two Dose levels of PF-02545920 Compared to Placebo in the Adjunctive Treatment of Outpatients with Sub-optimally Controlled Symptoms with Schizophrenia. 2014 - 2014 PI: Tran-Johnson
84. Otsuka Protocol 331-13-006: An Exploratory, Multicenter, Open-label, Monotherapy, Flexible-dose Brexpiprazole (OPC 34712) Trial in Adults with Early Episode Schizophrenia. 2013 - 2014 PI: Tran-Johnson
85. Otsuka Protocol 331-13-008: An Exploratory, Multicenter, Open-label, Flexible-dose Brexpiprazole (OPC-34712) Trial in Adults With Acute Schizophrenia. 2014 - 2014 PI: Tran-Johnson
86. Takeda Protocol TAK-375SL\_201: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL\_ Tablet) 0.1, 0.4, and 0.8 mg as an Adjunctive

Therapy in the Treatment of Acute Depressive Episodes Associated with Bipolar I Disorder in Adult Subjects. 2014 - 2015 PI: Tran-Johnson

87. Takeda Protocol TAK-375SL\_203: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375SL 0.1, 0.4, and 0.8 mg as an Adjunctive Therapy to Treatment-as-Usual in the Maintenance Treatment of Bipolar I Disorder in Adult Subjects. 2014 - 2014 PI: Tran-Johnson
88. Reckitt Benckiser Protocol RB-US-09-0010: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of RBP-7000 (90 mg and 120 mg) as a Treatment in Subjects with Acute Schizophrenia Over 8 Weeks (2 Subcutaneous Doses). 2014 - 2014 PI: Tran-Johnson **FDA Audit in 2018 with no 483s.**
89. Reckitt Benckiser Protocol RB-US-13-0005: An Open-label, Long-term Safety and Tolerability Study of RBP-7000 in the Treatment of Subjects with Schizophrenia. 2014 - 2016 PI: Tran-Johnson
90. Otsuka Protocol 331-12-282: A Phase 3, Multicenter, Randomized, Double-blind, Placebo- and Active Comparator-controlled Trial of Flexible-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder, the Delphinus Trial. 2014 - 2015 PI: Tran-Johnson
91. Otsuka Protocol 331-10-238: A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults with Major Depressive Disorder, the Orion Trial. 2015 - 2016 PI: Tran-Johnson
92. Intra-Cellular Protocol ITI-007-301: A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Antipsychotic Efficacy of ITI-007 in Patients with Schizophrenia. 2014 - 2015 PI: Tran-Johnson
93. Pfizer Protocol B7431007: An 8-week, Randomized, Phase 2, Double-blind, Sequential Parallel-group Comparison Study of Two Dose Levels of PF-06372865 Compared to Placebo as an Adjunctive Treatment in Outpatients with Inadequate Response to Standard of Care for Generalized Anxiety Disorder. 2015 - 2015 PI: Tran-Johnson
94. Intra-Cellular Protocol ITI-007-302: A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter Study to Assess the Antipsychotic Efficacy of ITI-007 After 6 Weeks of Treatment in Patients with Schizophrenia. 2015 - 2016 PI: Tran-Johnson
95. Avanir Protocol 15-AVP-786-202: A Phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of AVP-786 (deuterated [d6]-dextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q] as an adjunctive treatment in patients with residual schizophrenia. Avanir 15-AVP-786-202: A Phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of AVP-786 (deuterated [d6]-dextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q] as an adjunctive treatment in patients with residual schizophrenia. 2015 - 2016 PI: Benbow
96. Takeda Protocol LuAA21004\_402: A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine (5, 10 and 20 mg) in Adults with Major Depressive Disorder. 2015 - 2016 PI: Benbow
97. Intra-Cellular Protocol ITI-007-401: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of ITI-007 Monotherapy in the Treatment of Patients with Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder (Bipolar Depression). 2015 - PI: Benbow

98. Intra-Cellular Protocol ITI-007-402: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center study to Assess the Efficacy and Safety of ITI-007 Adjunctive to Lithium or Valproate in the Treatment of Patients with Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder (Bipolar Depression). 2016 - PI: Benbow
99. Pfizer Protocol B1701019: A 12-Week, Phase 2, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of PF-04958242 in Subjects with Cognitive Impairment Associated with Schizophrenia (CIAS). 2016 - 2016 PI: Chen
100. Noven Protocol HP-3070-GL-04: A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, 6-Week, In-Patient Study to Assess the Efficacy and Safety of HP-3070 in Subjects Diagnosed with Schizophrenia. 2016 - 2017 PI: Chen
101. Teva TV46000-SAD-10055: A Phase 1, Sequential, Single Ascending Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TV-46000, Risperidone Extended-Release Injectable Suspension for Subcutaneous Use, In patients with Schizophrenia or Schizoaffective Disorder. 2016 - 2018 PI: Chen
102. Otsuka Protocol 331-201-00033: A Phase 1, Two-part, Open-label, Randomized, Exploratory and Single Ascending Dose, Parallel Arm Trial to Determine the Pharmacokinetics, Safety, and Tolerability of Brexpiprazole Long-acting Injectable Administered Subcutaneously or Intramuscularly in Adult Subjects with Schizophrenia. 2017 - 2017 PI: Chen (as listed in clinicaltrials.gov)
103. Intra-Cellular ITI-007-303: An Open-Label, Multi-Center Trial to Assess the Safety and Effectiveness of ITI-007 in Patients with Schizophrenia 2017 - PI: Benbow
104. Pharmascience PAL-101: A Randomized, Crossover, Open-Label, Multiple Dose, Pivotal Pharmacokinetic Bioequivalence Study Comparing paliperidone palmitate extended-release IM 156 mg/1 mL (100 mg eq) with Invega Sustenna® (US Product Reference) in Subjects with Schizophrenia or Schizoaffective Disorder. 2017 - PI: Chen
105. Otsuka 031-201-00104: A Phase 1, Open-label, Single Ascending Dose, Parallel Arm Trial to Determine the Pharmacokinetics, Safety and Tolerability of Aripiprazole 2 Months Intramuscular Depot Administered Gluteally in Adult Subjects with Schizophrenia. (as listed in clinicaltrials.gov) 2017- PI: Chen
106. Allergan RGH-MD-25: A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-reduction Paradigm in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features 2018 - PI: Chen
107. Biogen 263CS201 A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS) 2018 - PI: Benbow
108. Boehringer Ingelheim 1346.9 : A Phase II, Randomized, Double-Blinded, Placebo-Controlled Parallel Group Trial to Examine the Efficacy and Safety of 4 Oral Doses of BI 425809 Once Daily over 12 Week Treatment Period in Patients with Schizophrenia 2018 - PI: Benbow
109. Astellas 4345-CL-0015: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subject with Schizophrenia on Stable Doses of Antipsychotic Medication. 2019 - 2020 PI: Benbow

110. Avanir 18-AVP-786-207: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Study to Assess the Efficacy, Safety, and Tolerability of AVP 786 (Deudextromethorphan Hydrobromide [d6 DM]/Quinidine sulfate [Q]) for the Treatment of Negative Symptoms of Schizophrenia. 2019 PI: Benbow
111. Otsuka 031-201-00301: A Phase IIIb Multi-center, Open-Label, Mirror-Image, Trial in Adult Subjects with Schizophrenia Treated Prospectively for 6-months with Abilify MyCite®. 2019 PI: Benbow
112. Roche BP40283: Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of RO6889450 in Patients with Schizophrenia of Schizoaffective Disorder and Negative Symptoms. 2019 PI: Benbow
113. Sunovion SEP361-302: A Randomized, Double-Blind, Parallel-group, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Subjects with Schizophrenia. 2019 PI: Benbow
114. Sunovion SEP361-303: An Open-label Extension Study to Assess the Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia. 2019 PI: Benbow
115. Boehringer Ingelheim 1346-0038: A Phase II, Randomized, Double-blinded, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of BI 425809 Once Daily with Adjunctive Computerized Cognitive Training Over 12-week Treatment Period in Patients with Schizophrenia. 2019 PI: Benbow
116. Otsuka 031-201-00181: A Phase 1b, Open-label, Multiple-dose, Randomized, Parallel-arm, Safety, Tolerability and Pharmacokinetic Trial of Aripiprazole Intramuscular Depot Administered in the Gluteal Muscle in Adult Subjects With Schizophrenia or Bipolar I Disorder. 2019 - PI: Chen